Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Assessment of the Efficacy & Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa

NCT00134134 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT00134134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00134134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Assessment of the Efficacy & Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa
Lead sponsor
NYU Langone Health
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2005
Completion date
August 31, 2006
Enrollment
5
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa